An astonishing US$8-billion (Bt240 billion) verdict against drug giant Johnson & Johnson by a jury in the United States this week was not just a potent rebuke of the company’s conduct but also represented what some analysts on Wednesday called a symptom of a growing anger at the broader pharmaceutical industry.